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A B S T R A C T 
 
In this work, a novel enteric coating based on natural waxes and alginate was reported. Initially, 
theophylline tablets were coated with emulsified ceresin wax in heated aqueous alginate 
solution using a fluidised bed coating technology. A coating level of 10% proved sufficient to 
prevent tablets from uptalking gastric medium (< 5%) and produced a delayed release profile 
that complies to the pharmacopeial criteria of enteric coating release. Then, a wide range of 
emulsions based on other natural waxes (white beeswax, yellow beeswax, cetyl palmitate, 
carnauba wax or rice bran wax) yielded coatings with similar disintegration times and release 
profiles. Interestingly, the ceresin-based coating showed a superior performance at inhibiting 
acid uptake and enabling highly pH-responsive drug release in comparison to different 
commercially available GRAS enteric coating products (Eudraguard® Control, Swanlac® 
ASL10, and Aquateric™ N100). The coating was stable for 6 months at 30°C and 65% RH. 
This innovative approach of applying hot O/W emulsion of natural waxes yielded an 
aesthetically attractive and stable coating with gastric protection and pH-sensitive release 
properties. The novel coating can be an efficient and promising alternative to overcome the 
shortcomings of current GRAS grade enteric coating products. 
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Nutraceuticals are herbal and food products that, in addition to their nutritional values, are 
used in treating or preventing diseases. The growing market of nutraceuticals exceeded $200 
billion last year (Chauhan et al., 2013; World, 2017). Several nutraceutical products require 
often functional enteric coating to protect them against the hostile gastric environment and/or 
to minimise irritation and mask unpleasant taste. Nutraceutical formulations often refrain from 
including artificial ingredients to favour the preferences and values of nutraceuticals 
consumers.  
Several enteric coating solutions, described as generally recognised as safe (GRAS), have been 
commercialised to respond to the high demand for nutraceutical product market (Barbosa et 
al., 2017). For instance, Sensient has developed a coating system known as Protect®, that relies 
on the use of naturally occurring shellac (Sensiet, 2019). However, developing shellac-based 
coating often involves the challenge related to  ammonium and suffers stability issues and 
batch-to-batch variations (Farag and Leopold, 2009). Nutrateric®, Eudraguard Control® and 
Biotic® are other examples of semi-synthetic and synthetic products that have also been 
recently introduced for the GRAS enteric coating of nutraceutical products. However, these 
products rely on the use of ammonium and their synthetic nature limits their daily intakes 
(Colorcon, 2017; GmbH, 2019).  
Naturally occurring waxes are esters of long chain acid and long chain alcohol (Akoh, 
2017). They offer a myriad of desirable characteristics such as fat dissolving, a wide range of 
melting points, and malleability under different processing conditions. Due to their natural 
origin and favourable characteristics, natural waxes have been widely incorporated in 
numerous food, cosmetic as well as drug delivery systems (Akoh, 2017; Moebus et al., 2012). 
Based on their origin, natural waxes are often categorised into plant, animal or mineral waxes. 
Plant waxes, also known as vegetable waxes, are found in the surface of leaves of palms e.g. 
carnauba wax from Copernicia prunifera. Beeswax is one of the most commonly used animal 
waxes that was used in pharmaceutical coatings for controlled and extended release systems 
(Kennedy and Niebergall, 1998; Lee et al., 2019). Ceresin wax, a purified lignite-free form of 
ozocerite wax, is a mineral wax which is often used in combination with other excipients to 
provide polishing, protective and/or sustained release coating (Bagaria and Lordi, 1987). In 
fact, waxes have been commonly used as matrix former in cores (e.g. pellets) for extended and 
controlled release (Hamdani et al., 2002; Tian et al., 2008; Zou et al., 2009). 
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The use of waxes in pharmaceutical coating is well-established as a finishing step to 
achieve polished glossy tablets (Kelley, 1948). Waxes, such as stearic and palmitic acids, have 
also been explored for their potentials to produce functional coatings with enteric properties. 
However, such approach delayed drug release (up to 4 hours following pH change) and failed 
to produce a functional enteric coating that complied with the pharmacopeial criteria (Patil et 
al., 2012). Indeed, purpose-designed enteric polymers are carefully engineered to dissolve 
rapidly upon the pH increase in intestinal segment (Barbosa et al., 2019). In contrast, waxes 
and lipids coating requires digestion by enzymes via lipolysis to allow the drug release 
(Zechner et al., 2012). This often result in a slow drug release for wax-based coated products. 
For instance, it has been shown that when combined with sustained release coating polymer, 
waxes can results in a further delay in drug release (Tian et al., 2008). More recently, bees wax 
solution in petroleum ether was used to coat Lactobacillus casei beads via deep coating and 
filtration method (Mandal et al., 2014), leading to an improved survival in gastric medium. Up 
to the authors’ knowledge, there has been no previous report of using waxes as an efficient 
functional enteric coating. 
Sodium alginate (Alg) is a GRAS-grade water soluble polysaccharide that has been widely 
used for pharmaceutical applications (Dalaty et al., 2016; Layek and Mandal, 2020). It has been 
used as pH-dependant pore-former in delayed release systems (Barbosa et al., 2019; Czarnocka 
and Alhnan, 2015). However, Alg water uptake and susceptibility to acidic hydrolysis hindered 
its use as a functional enteric coating on its own, despite its film forming properties (Pawar and 
Edgar, 2012). In this context, we have previously reported that incorporating fatty glycerides 
in Alg-based films yielded coating systems with pH-dependent release properties (Khoder et 
al., 2020). However, the coated cores showed a high acid uptake (≥25%), which might not be 
suitable for acid-labile active ingredients.  
In this work, we report for the first time an innovative approach to craft an all-natural 
enteric coating system by employing a hot O/W emulsion of natural waxes in Alg solution. The 
applicability of this approach was carefully assessed across a wide spectrum of naturally 
occurring waxes. The gastro-resistant properties of these novel coatings were established. 
Moreover, we have provided a head-to-head comparison against recently introduced GRAS-
grade enteric coating products, which have not been yet evaluated independently. Long-term 




2. Materials and methods 
2.1. Materials 
Theophylline anhydrous, a model drug, was purchased from Acros Organics (New Jersey, 
USA). The excipients used for tablet compression were  lactose monohydrate Lactopress 
(BASF SE, Germany), polyvinylpyrrolidone K90 (Sigma–Aldrich, Dorset, UK), 
microcrystalline cellulose (MCC) PH101 (FMC Biopolymer, Belgium), crosscarmellose 
sodium SD-711 (FMC Biopolymer, Belgium) and magnesium stearate (Sigma–Aldrich, 
Dorset, UK). The coating components were: sodium alginate (Alg) (15–20 cps, Sigma-Aldrich 
Dorset, UK), ceresin wax (Fisher Scientific UK), white bees (Acros, Belgium), yellow beeswax 
(Fischer Scientific, UK), carnauba wax (Sigma Aldrich, Dorset, UK), rice bran wax (donated 
by Koster Keunen, USA), and cetyl palmitate (Acros, UK). Glyceryl monostearate (GMS, 
Imwitor® 900K) was donated by Cremer OLEO (Germany). Methocel™ E5 Premium LV 
supplied by Colorcon (UK), Lycoat® RS 780 supplied by Roquette (France). Ammoniated 
shellac (Swanlac® ASL) was donated by AF Suter & Co Ltd. (UK). Aquateric™ N100 was 
supplied by FMC biopolymer (USA). Eudragaurd® Control was donated by Evonik 
(Darmstadt, Germany). 
2.2. Model Tablet Preparation 
The tablets were prepared by wet granulation as previously detailed (Czarnocka and 
Alhnan, 2015; Khoder et al., 2020). Briefly, powder blend (250 g of theophylline, 240 g of 
lactose monohydrate and 10 g of PVP K90) was granulated with 110 mL of Type II water using 
a mixer granulator (Erweka, Germany). Wet granules were then dried using a fan oven (Binder, 
Germany) to yield approximately 2-3% w/w moisture content to aid compression. Using a 
double-cone mixer (Erweka AR 402, Germany), the resultant granules (500 g) were blended 
for 10 min with 150 g of MCC, 350 g of Lactopress, 30 g of crosscarmellose sodium salt, and 
10 g of magnesium stearate. The tablets were manufactured using a single-punch tablet press 
(Riva Minipress, Argentina). The resultant tablets demonstrated an average weight of ~600 mg 
and a resistant to crushing force of 120 N. 
2.3. Preparation of films 
a. Casted film 
Alg, exemplar wax (ceresin wax) and GMS were firstly blended to produce different weight 
ratios (Alg: wax: GMS 12:4:1, 11:5:1, 10:6:1, 9:7:1 or 8:8:1 w/w/w). Obtained blends were 
then dispersed for 30 min at a concentration of 2.25% w/v in hot water (70 oC) under magnetic 
stirring of 150 rpm. Film casts were prepared by individually pouring 20 mL of the hot resulting 
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dispersions into a 100 mm Teflon-coated circular trays. Films were dried in a fan oven at 40 
oC for 24 hours. Upon drying, the resultant films were peeled off and evaluated for film 
formation property and homogeneity. 
b. Coated tablets  
Initially, blends of Alg, ceresin wax and GMS at different weight ratios (12:4:1, 11:5:1, 
10:6:1, 9:7:1 or 10:10:1 respectively) were prepared as mentioned above. Using magnetic 
stirring (150 rpm), obtained powders blends (9 g) were mixed for 45 min with 400 mL water 
kept at a temperature of 70 oC to yield final concentration of 2.25% w/v.  
Alg: ceresin wax: GMS ratio of 10:6:1 was selected as a default condition based on film 
forming property study and applied and tested at three coating levels; 5, 7 and 10% WG (weight 
gain). In order to assess the suitability of other naturally occurring waxes, the same blend ratio 
(Alg: wax: GMS 10:6:1) was applied to the model core at 10% WG by replacing ceresin wax 
with: white beeswax, yellow beeswax, cetyl palmitate, carnauba wax or rice bran wax. 
All coatings were carried out using a Strea-1 fluidised bed coater (GEA Pharma Systems AG,  
Bubendorf, Switzerland). The inlet air temperature was adjusted at 55 °C and outlet air 
temperature was 45 °C, yielding a tablet bed temperature of 42-45°C. The atomizing pressure 
was set at 0.35 Bar. During coating process, the coating solution was continuously stirred and 
maintained at 70 °C and the spray rate was ~3.4 mL/min. In order to prevent wax solidification 
within the tube that connects the bulk feed emulsion to the spraying nozzle, the tube was 
surrounded with an electric heating tube (BriskHeat, Columbus, OH, USA) and the temperature 
was maintained at 70 °C. 
2.4. Characterization of coating liquid 
The coating liquid based on Alg: wax: GMS (10:6:1) was prepared as stated in Section 2.3. 
To confirm the nature of emulation, 5 mg of a lipophilic dye (Nile Red) was added to the liquid 
at 70 oC under stirring. Aliquots of the preparation were analysed using temperature-controlled 
Leica light microscope equipped with QIClick camera and the images were processed using 
Q-Capture Pro 7 (Teledyne Imaging, Surrey, Canada). 
2.5.  Comparison with other commercial GRAS grade coating systems 
Commercially available GRAS grade enteric products; Eudraguard® Control (neutral 
methacrylic polymer + Alg),  Swanlac® ASL 10 (ammoniated ready solution of shellac + Alg), 
and Aquateric® N100 (Alg + soluble starch) were recently introduced to the market (Joao A.C. 
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Barbosa, 2017). In order to provide direct comparison with the novel developed coating, these 
coating systems were applied to the same model core following manufacturer information. 
i) Eudraguard® Control The coating was based on 5.2% dispersion of Eudraguard®  
Control (available as 30% w/v dispersion), 2.8% Alg, 0.4% glycerol , and 0.16% talc in 400 
mL deionized water to achieve a 10% w/v suspension (GmbH, 2015). The formulation was 
applied at different coating level; 2, 3, 4, 5, 7.5, and 10% WG. The coating was processed as 
detailed in Section 2.3 except for a flow rate of 2 mL/min. 
ii) Swanlac® ASL10 An aqueous solution of ammoniated shellac and alginate was 
prepared following Pencoat 770 formulation (AF Suter & Co Ltd.,UK). The coating solution 
was prepared by adding ammoniated shellac solution Swanlac® ASL10 (available as 25% w/v 
solution) to 375 mL of 2% Alg solution. The final solution has Shellac: Alg ratio of 7:3. The 
coating was applied at different levels: 2, 3%, 6%, 12% WG using parameters as detailed in 
section 2.3. 
iii) Aquateric™ N100 The coating was applied as described by Yang et al. (2016). An 
aqueous solution composed of 5% sodium alginate (Manucol LD, 10 cps), 3.4 % soluble starch 
(Lycoat RS 780) and 1.7% glycerol (plasticiser) was applied at different levels; 8%, 10%, 12% 
using parameters as detailed in section 2.3. 
 
2.6.  Thermal analysis 
Thermogravimetric analysis (TGA) test was carried out using TA Analysis Q500 analyser 
(TA Instruments, Hertfordshire, UK). Samples (10 mg of Alg, GMS, ceresin wax, physical 
mixture and the film) were individually weighed and placed in crimp-sealed aluminium pans. 
The temperature was scanned from 20°C to 500°C at a heating rate of 10 °C/min under a 
nitrogen gas flow of 40 and 60 mL/min for furnace and samples. The thermal decomposition 
(or degradation) profile was analysed using TA Universal Analysis 2000 software (TA 
Instruments, Hertfordshire, UK).  
Differential scanning analysis (DSC) was carried out using TA analysis 2000 (TA Instruments, 
Hertfordshire, UK). Sample of approximately 7 mg was weighed in a T0 pan and scanned from 
20 °C to 180 °C for the films and to 120°C for the single ingredients including the physical 
mixtures as most of natural waxes melting point lie between 40°C-140°C (Endlein and Peleikis, 
2011), . Samples were heated to 100 °C for 5 min to exclude the effect of humidity then cooled 
to -20 °C. This was followed by a heat-scan from -20 to 180 °C. Analysis was carried out under 
a purge of nitrogen (50 mL/min) at a heating rate of 10 °C/min. The data was analysed using 




2.7.  Morphology of the coating  
The colour and integrity of the coating were assessed using photographs taken by a D7100 
Nikon DSLR digital camera (Nikon, Japan) integrity. Cross-sections of the coated tablets were 
examined using a Quanta-200 scanning electron microscope (SEM) microscope at 20 kV. 
Samples were placed on metallic stubs and gold scattered under vacuum for 2 min using JFC-
1200 Fine Coater (Jeol, Tokyo, Japan), prior to imaging. 
 
2.8.  Disintegration test 
The disintegration test was conducted in accordance with United Stated Pharmacopeia 30 
standards (USP, 2007). Tablets (6 units) were placed in a ZT122 disintegration test apparatus 
(Erweka, Germany) that was operated for an hour in 800 mL 0.1 M HCl. Then the medium was 
replaced by intestinal pH 6.8 phosphate buffer, as specified in United Stated Pharmacopeia 30 
(USP 30). The experiment was continued until complete disintegration of all tablets. 
2.9. Acid Uptake 
In order to evaluate the gastric resistance and protection capabilities of coating system, dry 
mass (DM) of six tablets were individually recorded  and tablet were then placed for 1 hr in 
800 mL 0.1 M HCl at 37°C.The tablets were drained off excess acid using filter paper and the  
wet mass (WM) of tablets was recorded. The acid uptake percentage was calculated according 
to Equation 1: 
𝐴𝑐𝑖𝑑 𝑢𝑝𝑡𝑎𝑘𝑒 % = (
𝑊𝑀−𝐷𝑀
𝐷𝑀
) ∗ 100                                Equation 1   
2.10. In vitro drug release study  
To assess the efficiency of coating systems to meet the compendial expectations drug 
release study was conducted in an AT-70 Smart dissolution USP II apparatus (Sotax, 
Switzerland) using the pH change method. Briefly, one tablet was placed in 750 mL of acidic 
phase (0.1 M HCl, pH 1.2) for 2 h followed by 4 h release test in intestinal phase of either pH 
6.8 phosphate buffer or krebs bicarbonate buffer as simulated intestinal medium (1.18 mM 
KH2PO4, 24 mM NaHCO3, 118.07 mM NaCl, 4.69 mM KCl, 2.52 mM CaCl2, and 1.18 mM 
MgSO4·7H2O) (Alhnan et al., 2011).  
The dissolution test was performed at 37±0.5 °C with a paddle rotation at 50 rpm. ,  The 
percentage of released theophylline was determined at 5 min intervals by UV/vis 
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spectrophotometer (PG Instruments Ltd., UK) at the wavelength of 272 nm and path length of 
1 mm. Data were analysed using Automated Lab IDISis software version 2012 (Berkshire, 
UK). 
2.11.  Stability Studies 
The tablets stability was tested according to ICH guidelines at different climatic zones. The 
coated tablets were kept in high density polyethylene (HDPE) bottles (Fisher Scientific, UK) 
at room temperature, 30 °C 65% RH, or 40°C 75% RH in humidity-controlled incubator. The 
release profile, disintegration and acid uptake tests of the coated tablets (ceresin as an exemplar 





3. Results and discussion 
3.1. Coating system setup 
In this work, a novel enteric coating system based on emulsified waxes into aqueous 
Alg solution was developed. As waxes are immiscible with aqueous Alg solution, the addition 
of GMS,  as a non-ionic emulsifying agent (HLB value= 3.8) (Remington and Beringer, 2006), 
was needed to stabilise the emulsion. Using ceresin as wax exemplar, a series of emulsions of 
different Alg: wax: GMS ratios: 12:4:1, 11:5:1, 10:6:1, 9:7:1 and 10:10:1 was initially prepared 
and used to create casted films to be evaluated for their coating quality. When wax ratio was 
increased to 10:10:1, wax and polymer separation was visually evident (data not shown). Light 
microscope imaging of the liquid preparation at 70 °C confirmed the formation of O/W 
emulsion with the presence of oily droplets coloured by lipophilic dye (Nile Red) (Fig. 1A). 
Following cooling sample to room temperature, the droplets readily solidified to form 3-5 m 
sized wax particles (Fig. 1B).  
Theophylline is a biopharmaceutical classification system (BSC) Class I drug (Qiu et al., 
2009). The aqueous solubility and relatively small molecular weight suggested this drug as an 
ideal model drug to test the enteric coating efficiency (Alhnan et al., 2010). Obtained emulsions 
maintained at a temperature of 70 °C were used as feed liquids to coat theophylline model core 
tablets. Fig. 1C displays the dissolution profiles of theophylline from tablets coated with 
different weight gain (WG) levels of Alg: wax: GMS (10:6:1). While a coating level of 5% and 
7% released 80% and 50% of theophylline in the gastric phase respectively, increasing the 
coating level to 10% significantly prevented the drug release in the gastric medium (<5%). Yet 
it allowed a prompt release upon introducing the core to the intestinal medium (Fig. 1C). The 
immediate release of theophylline in the intestinal medium could be attributed to the immediate 
ionization of the carboxylic acid groups in Alg as the pH of the medium increases. Such 
ionisation can result in the electrostatic repulsion between negatively charged carboxylic 
groups, and hence the disintegration of the coating film and resulting dissolution (Hussan, 
2012). The obtained release profile using a 10% coating level fulfills the pharmacopeial criteria 
of enteric coating release. Fig. 1D illustrates the dissolution of theophylline from tablets coated 
with different Alg: wax ratios with a coating level of 10% and shows no significant impact on 
the drug release profiles (Fig.1 D). It is worth mentioning that tablets coated with Alg solely 
without natural waxes as a blend, failed to prevent the drug release in gastric medium (Khoder 
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et al., 2020). On the other hand, adding GMS to Alg led to a significant control in drug release 
in gastric phase while inhibition of acid uptake remained limited (Khoder et al., 2020).  
3.2 Morphology and characteristics of Alg- wax films 
Tablets coated with Alg- wax films showed tinge of yellow-colored surface. The coated 
tablets were glossy and smooth in texture showing a matt finish and uniform film (Fig. 2 A). 
SEM images indicated that these films were approximately 80-100 µm in thickness (Figs. 2 B 
and C).  
TGA thermographs of film components of Alg, GMS, and ceresin wax are shown in 
Fig. 3; no thermal degradation could be identified at the processing temperature (i.e. 70 °C). 
The drop in Alg weight (15%) at approximately 100 °C could be attributed to the evaporation 
of moisture contents (J. P. Soares, 2004). The DSC thermographs of the cast film individual 
ingredients illustrated an endothermic melting peak at approximately 59 and 64°C for ceresin 
wax and GMS respectively (O'Laughlin, 1989; Rowe, 2009) (Fig. 4A). DSC thermographs also 
showed a distinctive melting point (Tm) at approximately 58°C for the casted films (Figs. 4B), 
which corresponded to the melting point of ceresin wax. This was also observed in the 
thermographs of films based on different ratios of Alg: wax. The increased pattern in the 
endothermic melting peak might be attributed to presence of wax contents within the film. 
These peaks indicated that a significant portion of wax was in crystalline form within the film 
structure. While O/W emulsion contained molten wax droplet in aqueous Alg solution, upon 
evaporation of water during core coating and the sequential cooling down of the film 
temperature, it is possible that the wax droplet solidified into crystallized particles within the 
formed Alg matrix (Fig.1B).  
The disintegration times of tablets coated with Alg-wax based emulsion showed 
resistance to open or softening in acid phase (Table1). This could be attributed to the 
unionization of Alg carboxylic groups and the enhanced overall lipophilic properties of coating 
film due to the presence of  wax particles (Khoder et al., 2020; Lee and Mooney, 2012). 
Following pH change, the ionization of Alg polymeric chains followed by their dissolution 
resulted in a breakage of the coated film, leading to tablets disintegration within 11 min in 
simulated intestinal fluid (Table1).  
3.3 Suitability of other natural waxes 
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In order to establish the suitability of the system to accommodate other naturally 
occurring waxes, the model core was coated using identical coating process by employing a 
range of naturally occurring wax examples i.e. white beeswax, yellow beeswax, cetyl palmitate, 
carnauba wax as well as rice bran wax. All the used waxes yielded coated cores that were 
glossy and smooth with different degrees of tinges of yellow colour depending on the nature 
of the employed wax (Supplementary data, Fig. S1). 
Wax-based enteric coatings showed resistance to acid phase for 1 h and disintegrated 
in <15 min in simulated intestinal fluid pH 6.8 (Table 1). The acid uptake of the coated core 
following the exposure to gastric medium ranged between 4.75% and 9%. The observed 
variability in the acid phase uptake by coatings that are based on different waxes might be 
related to their chemical composition. In fact, the free fatty acid constituents and their 
percentages in each wax might play a significant role in maintaining local low pH (i.e. in the 
acid medium with non-ionized Alg), and hence decrease the acid uptake. Furthermore, the 
length of alkyl chain constituents can directly influence the hydrophobic nature of waxes 
resulting in lower permeability of the film in acid medium.  
When the drug release was tested using pH-change dissolution test (Fig.5 A), all waxes-
based coatings showed <10% release in the gastric phase followed by >80% released within 
45 min in intestinal media (pH 6.8), that confirmed their conformity to the pharmacopeial 
criteria for enteric coating. In order to assess the release quality in more biologically relevant 
gastric medium (Fadda et al., 2009; Horter and Dressman, 1997), the coated tablets were tested 
in Hanks bicarbonate buffer. While all coated tablets showed resistance of drug release in the 
acidic media, they displayed relatively slower responses to the pH change in the bicarbonate-
based buffer (Fig. 5 B). Nonetheless, the use of bicarbonate-based buffer allowed the 
differentiation of naturally occurring waxes. For instance, carnauba wax-based coating showed 
a relatively faster response to pH change with 80% release after 15 min in bicarbonate buffer 
pH 7.4, whilst cetyl palmitate and yellow beeswax-based coatings reached 80% release after 
35 min of pH change. However, other waxes-based coatings resulted in a further delay in the 
response to pH change. For instance, the rice bran wax-based coating took up to 3 hours in 
bicarbonate buffer pH 7.4 to reach the 80% release. The inclusion of wax resulted in the 
embedment of ionisable hydrophobic constituents within the coating matrix such as aliphatic 
acid, lignoceric acid, behenic acid, and other free fatty acids such as palmitic  acid (carbon 
atoms range from 26-30) (Tiwle, 2015). The presence of such lipophilic molecules might 
contribute to the reduced water imbibition into the coating matrix. Furthermore, the slower 
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response of the coating to the bicarbonate buffer could be attributed to its lower buffer capacity 
when compared with phosphate buffer (Liu et al., 2011). Indeed, the lower buffer capacity 
might have resulted in delayed ionization of the alginic and fatty acids, hence resulted in slow 
dissolution.  
These findings are of a significant importance as our previous report indicated that 
several commercially available coatings failed to dissolve at sufficient time in bicarbonate 
based gastric medium (Czarnocka and Alhnan, 2015). It is also important to highlight that this 
unique formulation approach, while providing a sufficient protection in acid medium, it 
maintained a timely pH-responsive behavior. 
3.4 Comparison with recently introduced GRAS-grade enteric coating  
The gastric resistant properties of this novel natural coating were directly compared to 
some GRAS-grade coating solutions which were recently introduced to the market. The 
dissolution profiles of different levels of these coating products as well as their gastro-resistant 
properties are shown in Fig. 6 and Table 2. 
Fig. 6.A shows that Eudraguard® Control (neutral methacrylic polymer + Alg), a 
minimal coating level of 2% was required in order to achieve a coating coverage that required 
that allow a sufficient inhibition for drug release in gastric medium. The addition of neutral 
methacrylic polymers seems to reduce the extent of Alg dissolution and maintained the 
integrity of the coating layer within the acidic medium. Upon pH change, a pH response was 
demonstrated after approximately 1 h. Furthermore, this combination showed a significant acid 
uptake (Table 2). While further increase in the coating thickness reduced the acid uptake, it 
resulted in a slower pH response of drug release beyond compendial expectations of delayed 
release products (Fig.6A). The slower pH response in comparison with wax-Alg based coating 
might be related to the slow dissolution rate of the non-ionizable methacrylic polymer chains 
compared to Alg. 
On the other hand, shellac-Alg-based coating (Swanlac® ASL 10) demonstrated gastric 
resistant properties with low acid uptake (Table 3) and <10% release in acid phase at pH 1.2. 
However, this coating system showed a slow pH response (up to 3 h) when the pH was changed 
to 6.8 (Fig.6B). It has been reported that shellac has a high dissolution threshold (pH 7.3) (Farag 
and Leopold, 2009; Limmatvapirat et al., 2007). Therefore, the dissolution test was repeated 
for this product using pH change dissolution method to pH 7.4. However, theophylline release 
was also slow in the intestinal phase (pH 7.4) (Fig. 6C). These findings were in agreement with 
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our earlier report of another shellac-Alg-based coating (Protect TM) (Czarnocka and Alhnan, 
2015). More recently, soluble starch (Lycoat® RS780) (Popescu et al., 2011) was included in 
an enteric coating design (Aquateric™ N100) in an attempt to hinder Alg dissolution and 
prevent film rupture from highly soluble Alg (Berger, 1953). However, the coating failed to 
inhibit drug release even (at WG level of up to 12%), with theophylline release percentage 
>10% and acid uptake of >50% (Table 4 and Fig. 6D).  
4.5 Stability studies 
Following storage at room temperature and at 30°C/65 RH% condition, wax-based 
coated tablets demonstrated a stable performance after 6 months with no significant difference 
in terms of release profile, disintegration time, physical appearance and acid uptake values 
(Figs. 7 A and B). However, while coating was relatively stable after 1 and 3 months at 40 °C 
75% RH, the coating allowed the drug release at acid phase at the 6-month time point (Fig. 
7C). This could be explained by the possible wax-softening upon storage for elongated period 
at elevated temperature. In fact,  most waxes tend to congeal at a lower temperature than their 
melting points (<50°C) (NIIR, 2006). Although these initial stability trials indicated a suitable 
shelf-life for many nutraceutical products, further research on immobilizing wax molecules 
might improve the long-term stability of this novel coating solution. 
4. Conclusion 
We reported a novel enteric coating based on purely naturally occurring materials 
(natural waxes, Alg and fatty glycerides). Using a hot O/W emulsion of waxes in Alg aqueous 
solution, attractive films with gastric-resistant properties were produced. An ideal wax 
percentage of 25-43%w/w within Alg-based film (i.e. Alg: wax ratios of 2:4 to 9:7) deemed 
necessary to minimise acid uptake and meet compendial criteria for delayed release products. 
The described coating method proved applicable to a wide range of naturally occurring waxes. 
The novel coating system also demonstrated superior gastro-resistant properties when 
compared with other of commercially available GRAS-grade coating solutions designed for 
the nutraceutical market. Due to the non-synthetic nature of its constituents, this novel coating 
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Table 1 Gastric resistance properties of naturally occurring wax based enteric coating following USP disintegration and dissolution tests. 
 Ceresin wax White beeswax Yellow Beeswax Cetyl palmitate Carnauba wax Rice wax 
In vitro drug release In phosphate 
buffer* 
✓ ✓ ✓ ✓ ✓ ✓ 
Lag time in buffer stage (min) 5 15 15 20 20 15 
80% release time in buffer stage (min) 45 35 40 40 45 35 
Disintegration test* ✓ ✓ ✓ ✓ ✓ ✓ 
Acid medium resistance Resisted Resisted Resisted Resisted Resisted Resisted 
Disintegration time of all tablets in SIF 
(min) 
10.2 10.9 11.1 11.4 10.7 11.6 
Acid uptake tests*       
Weight gained (%) 4.75% 5.25% 9% 8.4% 9% 6% 
In vitro drug release In bicarbonate 
buffer* 
      
Lag time in buffer stage (min) 60 30 15 15 5 90 
80% release time in buffer stage (min) 90 70 35 35 10 90   

















In vitro drug release In phosphate 
buffer* 
✓ ✓ ✓ ✓ ✓ ✓ 
Lag time in buffer stage (min) 30 35 40 ? ? ? 
80% release time in buffer stage (min) 110.3 47.5 62.5 >180 >180 >180 
Disintegration test* ✓ ✓ ✓ ✓ ✓ ✓ 
Acid medium resistance Resisted Resisted Resisted Resisted Resisted Resisted 
Disintegration time of all tablets in SIF 
(min) 
>120 >120 >120 >180 >180 >180 
Acid uptake tests*       
Weight gained (%) 12.9% 11.2% 9% 8.7% 8.43% 8% 





Table 3 Gastric resistance properties of Swanlac ASL enteric coating following USP disintegration and dissolution tests. 




In vitro drug release In phosphate buffer* ✓ ✓ ✓ 
Lag time in buffer stage (min) 15 40 ? 
80% release time in buffer stage (min) >180 >180 >180 
Disintegration test* ✓ ✓ ✓ 
Acid medium resistance Resisted Resisted Resisted 
Disintegration time of all tablets in SIF 
(min) 
>120 >120 >120 
Acid uptake tests*    
Weight gained (%) 1.7% 1.8% 1.9% 
 




Table 4 Gastric resistance properties of Aquateric N100 (Alg + LYCOAT RS780) enteric coating following USP disintegration and dissolution tests. 
 Aquateric N100 8% Aquateric N100 10% Aquateric N100 12% 
In vitro drug release In phosphate buffer* ✓ ✓ ✓ 
Lag time in buffer stage (min) 0 0 5 
80% release time in buffer stage (min) 155 45.3 69.8 
Disintegration test* X  X  X  
Acid medium resistance Disintegrated Disintegrated Disintegrated 
Disintegration time of all tablets in SIF (min) - - - 
Acid uptake tests*    
Weight gained (%) 100% 56.7% 53.9% 
* Criteria for enteric coating system: ✓pass, X fail 
 
